Antiemetics in children receiving chemotherapy

Only a few studies have been carried out in children on the prevention of chemotherapy-induced acute emesis. 5-HT3 antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. The optimal dose and scheduling of the 5-HT3 antagonists has not...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2005-02, Vol.13 (2), p.129-131
Main Authors: Roila, Fausto, Feyer, Petra, Maranzano, Ernesto, Olver, Ian, Clark-Snow, Rebecca, Warr, David, Molassiotis, Alexander, Molassiotos, Alexander
Format: Article
Language:English
Subjects:
Antiemetics - therapeutic use
Antineoplastic Agents - adverse effects
Chemotherapy
Child
Dexamethasone - therapeutic use
Drug therapy
Drug Therapy, Combination
Humans
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Serotonin 5-HT3 Receptor Antagonists
Vomiting - chemically induced
Vomiting - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Only a few studies have been carried out in children on the prevention of chemotherapy-induced acute emesis. 5-HT3 antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. The optimal dose and scheduling of the 5-HT3 antagonists has not been identified. Combinations of a 5-HT3 antagonist and dexamethasone show increased efficacy with respect to 5-HT3 antagonists alone. All pediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children.
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-004-0702-6